Bayer gains access To Mammoth Biosciences’ gene-editing technology

Published by
DPA

German pharmaceuticals company Bayer and Mammoth Biosciences have entered a strategic collaboration and option agreement for the use of Mammoth’s CRISPR systems to develop in vivo gene-editing therapies. CRISPR is a gene-editing technology that allows scientists to snip out and insert genes and sequences to create new biological processes. Mammoth Biosciences will receive an upfront payment of 40 million dollars and is eligible to receive target option exercise fees as well as potential future payments in the magnitude of more than 1 billion dollars upon successful achievement of certain miles…

Read More

Leave a Reply